Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Kerstin Stemmer; Brian Finan; Richard D. DiMarchi; Matthias H. Tschöp; Timo D. Müller

doi:10.1016/j.addr.2020.05.008

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Kerstin Stemmer
, Brian Finan
, Richard D. DiMarchi
, Matthias H. Tschöp
, Timo D. Müller

Medicine and Health

Helmholtz Zentrum München German Research Center for Environmental Health
Universitat Konstanz
Novo Nordisk Research Center
Indiana University Bloomington
Universitätsklinikum Tübingen

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

Original language	English
Pages (from-to)	34-53
Number of pages	20
Journal	Advanced Drug Delivery Reviews
Volume	159
DOIs	https://doi.org/10.1016/j.addr.2020.05.008
State	Published - Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Diabetes
Dyslipidemia
Incretins
Lipoproteins
Obesity

Access to Document

10.1016/j.addr.2020.05.008

Cite this

@article{19be243e53e94f3d8f46313c6918fad1,

title = "Insights into incretin-based therapies for treatment of diabetic dyslipidemia",

abstract = "Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.",

keywords = "Diabetes, Dyslipidemia, Incretins, Lipoproteins, Obesity",

author = "Kerstin Stemmer and Brian Finan and DiMarchi, \{Richard D.\} and Tsch{\"o}p, \{Matthias H.\} and M{\"u}ller, \{Timo D.\}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = jan,

doi = "10.1016/j.addr.2020.05.008",

language = "English",

volume = "159",

pages = "34--53",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Insights into incretin-based therapies for treatment of diabetic dyslipidemia

AU - Stemmer, Kerstin

AU - Finan, Brian

AU - DiMarchi, Richard D.

AU - Tschöp, Matthias H.

AU - Müller, Timo D.

PY - 2020/1

Y1 - 2020/1

N2 - Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

AB - Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

KW - Diabetes

KW - Dyslipidemia

KW - Incretins

KW - Lipoproteins

KW - Obesity

UR - https://www.scopus.com/pages/publications/85086358886

U2 - 10.1016/j.addr.2020.05.008

DO - 10.1016/j.addr.2020.05.008

M3 - Review article

C2 - 32485206

AN - SCOPUS:85086358886

SN - 0169-409X

VL - 159

SP - 34

EP - 53

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this